BioCentury
ARTICLE | Company News

Xenova, QSV Biologics Ltd. deal

September 6, 2004 7:00 AM UTC

XEN sold its Canadian manufacturing facilities to QSV Biologics for £2.9 million ($5.2 million). XEN will receive $3.8 million in cash up front, and the remaining $1.5 million in two equal secured promissory notes maturing 12 and 18 months following completion of the sale. Additionally, QSV will manufacture and supply XEN's TransMid. The diphtheria toxin conjugated to transferrin (immunotoxin) is in Phase III trials to treat non-resectable, progressive or recurrent glioblastoma multiforme. ...